Guangzhou LBP Medicine Science & Technology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Guangzhou LBP Medicine Science & Technology Co., Ltd. - overview
Established
2005
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Founded in 2005 and based in Guangzhou, China, Guangzhou LBP Medicine Science & Technology Co. , Ltd. develops pathology diagnostic equipment, reagents, and digital pathology systems for medical institutions. The company has built full-chain capabilities covering raw materials, pathology laboratory equipment, software platforms, and pathology service solutions.
It operates three R&D centers in Guangzhou, Shanghai, and Suzhou and serves nearly 3,000 medical institutions across China. Its product portfolio includes LBC, IHC, FISH, and digital pathology technologies. In August 2020, the firm was listed on the Shanghai Stock Exchange under the ticker 688393. The company works with hospitals and pathology laboratories to provide diagnostic equipment, reagents, consumables, and digital pathology software supporting LBC, IHC, FISH, and digital pathology workflows.
Current Investors
GTJA Investment Group, CCB International Asset Management, CDF-Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.gzlbp.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Guangzhou LBP Medicine Science & Technology Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 260,469,661.7 | 306,296,198.6 | 355,159,969.6 | 374,568,046.9 | 438,988,843.6 | - | - | - |
| % Revenue Growth (YoY) | - | 17.6% | 16.0% | 5.5% | 17.2% | - | - | - |
| EBITDA (USD) | 73,745,700 | 87,681,200 | 100,087,600 | 105,791,402.4 | 105,466,907.6 | - | - | - |
| Operating Income (USD) | 60,645,864.1 | 74,362,961.5 | 88,796,449.4 | 94,149,520 | 88,940,167.7 | - | - | - |
| Operating Margin | 23.3% | 24.3% | 25.0% | 25.1% | 20.3% | - | - | - |
| % EBITDA Margin | 28.3% | 28.6% | 28.2% | 28.2% | 24.0% | - | - | - |
| NET Income (USD) | 49,741,398.5 | 62,419,792.1 | 72,803,987.5 | 83,622,219.4 | 75,282,437.8 | - | - | - |
| % Net Margin | 19.1% | 20.4% | 20.5% | 22.3% | 17.1% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.